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Abstract: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western
World and it is characterized by a marked degree of clinical heterogeneity. An impaired balance
between pro- and anti-apoptotic stimuli determines chemorefractoriness and outcome. The low
proliferation rate of CLL cells indicates that one of the primary mechanisms involved in disease
development may be an apoptotic failure. Here, we study the clinical and functional significance of
DRAK2, a novel stress response kinase that plays a critical role in apoptosis, T-cell biology, and B-cell
activation in CLL. We have analyzed CLL patient samples and showed that low expression levels of
DRAK2 were significantly associated with unfavorable outcome in our CLL cohort. DRAK2 expression
levels showed a positive correlation with the expression of DAPK1, and TGFBR1. Consistent with
clinical data, the downregulation of DRAK2 in MEC-1 CLL cells strongly increased cell viability and
proliferation. Further, our transcriptome data from MEC-1 cells highlighted MAPK, NF-κB, and Akt
and as critical signaling hubs upon DRAK2 knockdown. Taken together, our results indicate DRAK2
as a novel marker of CLL survival that plays key regulatory roles in CLL prognosis.
Keywords: CLL; DRAK2; STK17B; prognostic indicator; DAPK1
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1. Introduction
Chronic lymphocytic leukemia (CLL) represents the most common adult leukemia in the western
world, accounting for ~40% of adult leukemia [1,2]. It is a malignancy of mature clonal B-lymphocytes
that accumulate in the blood, bone marrow, and lymphoid tissues [2,3]. The immunophenotype of
CLL is defined by the expression of B-cell markers (CD23, CD19, and weak CD20), along with the CD5
antigen and weak expression of surface membrane immunoglobulin (sIg) [4]. Despite the well-defined
morphological and immunological phenotype, the clinical course and outcome of CLL are highly
heterogeneous [4,5].
Unlike other B-cell malignancies, CLL is not usually associated with chromosomal translocations.
Cytogenetic abnormalities, such as deletions of 13q14, 11q22-q23, and 17p13, trisomy 12 [6],
and high-level expression of serum markers (CD38, Zeta-chain-associated protein kinase 70 (ZAP-70))
are critical predictors of disease progression and survival [7–10]. Unmutated IGVH (U-IGVH) cases
have more aggressive disease and shorter survival times than those with mutated IGVH (M-IGVH) [11].
In addition, 15% of CLL show aberrations in a few frequently affected chromosomal regions, including
ATM and TP53 genes, which are correlated with disease progression and overall survival [4,12].
The precise etiology of CLL remains to be determined, although it is well-known as a
lympho-proliferative disease. Patient CLL cells have been shown to be arrested in the G0/G1
phase of the cell cycle [13], resulting in low proliferation and accumulation of malignant cells that are
unable to initiate their apoptotic program in blood, lymphoid tissues, and bone marrow [14]. In line
with this observation, the impaired balance between pro- and anti-apoptotic stimuli is established
to play key roles in chemorefractoriness and outcome of CLL [14]. Moreover, the extrinsic and the
intrinsic apoptotic pathways and their regulators, such as DR4 (Death Receptor 4), TNF receptor type
1-associated death domain protein (TRADD), Fas-associated protein with death domain (FADD) and
tumor necrosis factor (TNF) receptor, have been implicated in CLL development [15,16].
The death-associated protein kinase family (DAPKs) are novel stress response, serine threonine
kinases, belonging to the calmodulin-regulated kinase family that have been strongly established to play a
critical role in apoptosis through intrinsic, extrinsic, and p53 mediated signaling cascades [17,18]. DAPKs
contain a catalytic kinase domain, death domain, ankyrin repeats, leucine zipper and a dimerization
domain that are shown to regulate multiple cell processes [18]. In extrinsic apoptotic signaling, the
DAPKs function downstream of receptors that respond to IFN-γ, TNF-α, FAS, and TGF-β-induction [17].
In familial, as well as sporadic CLL, loss or reduced expression of DAPK1 due to epigenetic silencing
by promoter methylation has been reported [19,20], however the precise function of DAPKs in CLL
remains unclear. In addition to DAPK1, the DAPK family includes DAPK2, DAPK3, DAP kinase-related
apoptosis-inducing protein kinase 1 (DRAK1), and DRAK2 [8,17].
In contrast to DAPK1, the other DAPKs and DRAKs have no death domain or calmodulin-binding
site, but include a N-terminal catalytic domain and a C-terminal region that is responsible for the
regulation of kinase activity and various cell signaling cascades [21] (Figure 1A,B). DRAK2 is a
lymphoid kinase, expressed in T and B cells [21]. In T cells, DRAK2 is involved in setting the threshold
for T cell activation, and its deficiency in T cells results in response to suboptimal stimuli, ultimately
leading to a defect in survival [22]. DRAK2 and protein kinase D (PKD) form a signaling module
that controls calcium homeostasis upon T-cell activation [23]. The drak2−/− mice showed a five-fold
decrease in spleen germinal centers compared to their wild-type littermates, resulting from increased B
cell apoptosis [24]. Since B-cell proliferation in the germinal center drives ongoing antigen-dependent
selection and generation of high-affinity class-switched plasma and memory B-cells, it is likely that
DRAK2 regulates these immune response signaling processes through its apoptotic function [24].
Conversely, suppression of apoptosis through DRAK2 occurs in acute myeloid leukemia through
upstream regulation of MYB oncogene [25]. Here, we have investigated the role of DAPK1 and DRAK2
in CLL biology and pathogenesis. We found only DRAK2 to have prognostic significance. Further,
the influence of DRAK2 on cell survival, proliferation, and gene expression suggests a possible role for
DRAK2 in CLL biology.
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with a high and low level of DRAK2 expression. 
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‘High’ and ‘Low’ expression sets (Figures S1A,B). DAPK1 RNA expression did not predict overall 
patient survival (OS) in our CLL cohort (Figure S1C). In contrast, DRAK2 low-expressing patients 
showed a significantly shorter OS than DRAK2 high-expressing patients (p = 0.003), suggesting that 
DRAK2 could be a new prognostic indicator in CLL (Figure 1C). DRAK2 expression was also linked 
to OS among the subgroup of patients with deletions of the long arm of chromosome 13 (13q), a 
recognized good prognostic group in CLL (Figure 1D). It was also noteworthy that in both univariate 
and multivariate models, the established biomarkers (age, 17p deletion, and IGHV status) and DRAK2 
expression remained strong predictors of OS (Table 2). No significant correlation was identified 
between the expression of DRAK2 and known clinical (age, IGHV status, mutation of TP53, and status 
of ZAP70 and CD38) and cytogenetic (13q, 11q, 17p deletions and trisomy 12) markers (Table 3; Figure 
S2A). CLL patients with a high white cell count or harboring 11q deletions were significantly more 
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2. Results
2.1. Low DRAK2 Expression Level Is Associated with Shorter Overall Survival in CLL Patients
RNA expression of DAPK1 and DRAK2 was measured in a cohort of 102 CLL patient-derived
samples (Table 1). Expression of DRAK2 and DAPK1 showed high variability between samples
(Figure 1A,B, lower panels). ROC (receiver operating characteristic) analysis was used to assign ‘High’
and ‘Low’ expression sets (Figure S1A,B). DAPK1 RNA expression did not predict overall patient
survival (OS) in our CLL cohort (Figure S1C). In contrast, DRAK2 low-expressing patients showed a
significantly shorter OS than DRAK2 high-expressing patients (p = 0.003), suggesting that DRAK2 could
be a new prognostic indicator in CLL (Figure 1C). DRAK2 expression was also linked to OS among
the subgroup of patients with deletions of the long arm of chromosome 13 (13q), a recognized good
prognostic group in CLL (Figure 1D). It was also noteworthy that in both univariate and multivariate
models, the established biomarkers (age, 17p deletion, and IGHV status) and DRAK2 expression
remained strong predictors of OS (Table 2). No significant correlation was identified between the
expression of DRAK2 and known clinical (age, IGHV status, mutation of TP53, and status of ZAP70
and CD38) and cytogenetic (13q, 11q, 17p deletions and trisomy 12) markers (Table 3; Figure S2A).
CLL patients with a high white cell count or harboring 11q deletions were significantly more likely to
have low DAPK1 expression (Figure S2B), indicating a preferential downregulation of DAPK1 within
these high-risk subgroups.
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Table 1. Clinical and molecular characteristics of the CLL cohort used in this study.
Characteristics N Percentage
Age ≥ 65 65 63.7
Sex: Male 71 69.6
Binet stage n = 90
A 49 54.4
B 16 17.8
C 25 27.8
IGHV status n = 63
Mutated 38 60.3
Unmutated 25 39.7
TP53 status n = 100
Mutated 12 12
Unmutated 88 88
Cytogenetics n = 101
13q 62 61.4
11q 20 19.8
12+ 6 5.9
17p 8 7.9
Normal karyotype 24 23.8
ZAP70 status n = 19
>20% 9 47.4
<20% 10 52.6
CD38 status n = 36
>20% 13 36.1
<20% 23 63.9
Treatment status n = 102
Treated 35 34.3
Untreated 67 65.7
Table 2. Overall Survival analyses of the established CLL biomarkers (age, 17p deletion, and IGHV
status) and the DRAK2 expression.
Covariate HR STD Err p-Value Conf. Interval HR STD Err p-Value Conf. Interval
Univariate Analysis Multivariate Analysis
Age > 70 years 1.05 0.02 0.014 1.01 1.091 1.094 0.026 0.001 1.04 1.151
17p status 3.681 0.542 0.016 1.273 10.65 3.188 0.619 0.06 0.947 10.729
IGHV status 3.093 0.418 0.007 1.363 7.02 5.514 0.473 0.0003 2.183 13.925
DRAK2
expression 0.343 0.379 0.005 0.163 0.722 0.428 0.427 0.04 0.185 0.987
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Table 3. Correlation analysis between relative expression of DRAK2 and common clinical and molecular
biomarker in CLL.
13q
Status
11q
Status
+12
Status
17p
Status Age Gender ZAP70 CD38 IGHV
TP53
Mut
RQ
DRAK2
Pearson r 0.014 −0.178 −0.064 −0.075 −0.033 −0.068 −0.267 −0.129 −0.111 −0.028
p 0.892 0.075 0.524 0.456 0.741 0.495 0.270 0.453 0.387 0.783
N 101 101 101 101 102 102 19 36 63 100
2.2. DRAK2 Expression Level Positively Correlates with DAPK1, and TGFBR1
A very strong positive correlation was found between the expression levels of DAPK1 and DRAK2
(Figure 2A,B). It has been shown previously that in solid tumours transforming growth factor β
Receptor I (TGFBR1) controls TGF-β/Smads signalling through DRAK2 [26]. Interestingly, in our
CLL patient cohort, a positive correlation was detected between DRAK2 and TGFBR1 (Figure 2B).
These data indicate a potential relationship between DRAK2 expression and other critical regulators of
cell survival in CLL.
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Figure 2. Correlation between DRAK2 and key targets of survival cellular pathways. Pearson’s
correlation analysis showing strong, positive relationship between (A) DAPK1 and DRAK2 RNA
expression and (B) TGFBR1 and DRAK2 RNA expression.
2.3. Subcellular Localization of K2
Further, we investigated DRAK2 subcellular localization in CLL. Previously DRAK2 has been
shown to localize within the nucleus through its ‘nuclear localization signal (NLS)’ motif in colon
cancer cells and fibroblasts [27]. However, other studies have established a compelling role for DRAK2
near the plasma membrane by controlling T cell tonic signal ng through the T-cell receptor directly
interacting with TGFBR1, thereby regulating smad signaling [26]. When we studied the cellular
localization of DRAK2 in MEC-1 cells using immunofluorescence, DRAK2 protein was found to be
located within the cytoplasmic as well as nuclear compartments. However, the predominant levels of
DRAK2 protein were present within the ucleus (Figure 3). Interestingly, within the cytoplasm, DRAK2
was located together with the actin filaments, indicating a possible role in cell adhesion, migration,
and proliferation.
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were stained with different fluorophores to visualize cellular compartments: cytoplasm/actin fila ents
(visualized with phalloidin) and nucleus (visualized with DAPI). Cells were analyzed using a ZEISS
Axio Imager microscope. Z1 to generate 2D view (A) using ZEISS Apotome that allows the collection
of confocal-like “Z” stacks to project images, as shown in 3D (B,C).
2.4. DRAK2 Impacts on Cell Viability and Proliferation
The functions of DRAK2 in relation to cell survival and proliferation are reported to be cell
type-dependent. For example, in triple-negative breast cancer, DRAK2 depletion clearly decreased
proliferation and tumorigenic breast cancer cells’ capacity through negative regulation of TGFβR1 [26].
In contrast, DRAK2 does not appear to function as the negative regulator of TGFβ signaling in primary
T cells [28]. Conversely, in pancreatic beta cells, apoptosis was induced upon overexpression of DRAK2
by interfering with Bcl-xL, Bcl-2, and Flip anti-apoptotic factors [29]. As DRAK2 expression in CLL
patient samples appears to play a tumor-suppressive, pro-apoptotic role, we studied the role of DRAK2
in cell proliferation and apoptosis in CLL. To facilitate gene manipulation studies, the CLL cell line,
MEC-1 was used to probe for the functional effects of DRAK2 knockdown or expression. MEC-1 cells
were transfected with plasmid DNA (expressing full-length DRAK2) or siRNA, to obtain DRAK2
cellular variants with up- or down-regulated gene and protein expression, respectively (Figure S3).
Using DRAK2 siRNA, 60% reduction in mRNA, and 50% reduction at the protein level were achieved
(Figure S3). The transfection of MEC-1 cells with DRAK2 plasmid DNA through nucleofection resulted
in 65-fold increase in mRNA and 20% increase in protein levels (Figure S3A,B). We studied the
influence of DRAK2 on cell proliferation in MEC-1 cells by measuring cell viability using trypan blue
staining and quantitation of ATP levels as an indicator of metabolically active, proliferating cells via
a luminescent-based assay. Both tests revealed that DRAK2 downregulation increased cell viability
(by 20–37%), while its overexpression reduced cell viability by 20–30% at the 24 h time point of analysis.
Importantly, this tendency was sustained for 48 h when cells were analyzed using the trypan blue
exclusion assay (Figure 4A,B). Furthermore, to estimate the cell proliferation rate, we analyzed the
proportion of cells that incorporated EdU (5-ethynyl-2′-deoxyuridine) during DNA synthesis. Results
showed that lack of DRAK2 increased cell proliferation by around 80% at 24 h, while high levels of
DRAK2 temporarily suppressed cell proliferation (40% at zero time point when compared to the mock
control) (Figure 4C), indicating that DRAK2 plays a role in the regulation of this cellular process.
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Figure 4. DRAK2 impact on the cellular viability (A,B) and proliferation (C). Cellular viability
was measured using the CellTiter-Glo® Luminescent Cell Viability Assay (A), trypan blue
staining (B), and the cell proliferation endpoint was evaluated by cell counting following EdU
(5ethynyl-2′-deoxiuridine) (C). All experiments were repeated 3 times, and error bars represent the
standard error of the mean of 5 experiments.
2.5. Impact of DRAK2 on Gene Expression in MEC-1
To analyze changes in the gene expression due to the downregulation of DRAK2 in MEC-1 cells and
provide overview of the affected genes and pathways, we used transcriptome arrays (Affymetrix,
Human Transcriptome Array 2.0). Upon DRAK2 knockdo n (Figure 5A,B), we identified 3691
differentially expressed tra scri ts (FC = 1.2, FDR < 0.05, p-value < 0.05) (Figure 5C, Supplementary
Materials Excel Fil S1). We pe formed data reduction by selecting 754 differentially expressed
transcripts with a fold change of 1.5, FDR < 0.05, p-value < 0.05. Among th differentially expressed
transcripts, 465 non-coding transcripts, including piRNA, lincRNA, lncRNA, and pseudogenes,
were eparated (Figure S ). Among 289 mapped transcripts, the u - and down-regulated transcripts
and the c ll ignaling pathways influenced by them were identifi using ingenuity pathway analysis
(IPA). Gene enri hment within pathways that regulate cell death, growth, proliferation, hematological
system, and developmental pathways w re implicated (Figure 5E, Figure S5). IPA analysis further
revealed key genes and pathways, including inflammatory disease, organismal injury, connectiv
tissue disorders, and immune cell t afficking, influenc d by DRAK2 dow regulation (Figure S5).
Among genes representative of th s pathway, we identified both pro- and anti-apoptotic genes,
as well as ge es involved in cell proliferation. Cell death a d survival emerged as th pathway m st
significantly deregulated upon DRAK2 knockdown, as MAPK, NF-κB, and Akt sign ling hubs were
i pacted (Figure S5). This study has reported, for the first time, an ass iati n between DRAK2
expression and poor prognosis in CLL and the possible nfluence of DRAK2 in cell survival and
proliferation of this disease.
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Figure 5. Microarray analysis reveals that MEC1 cells produce a differential gene expression signature
upon DRAK2 siRNA knockdown. (A) DRAK2 siRNA knockdown in MEC1 cells strongly reduces
DRAK2 RNA and (B) protein levels. (C) Volcano plot in which gene expression is calculated as
a linear fold change relative to MEC1 cells treated with siRNA control. p-value is calculated by
one-way between-subject ANOVA for unpaired samples. Red data points represent genes expressed
> 1.2-fold and blue data points represent genes expressed < 1.2-fold in MEC1-siRNA-DRAK2 versus
MEC1-siRNA-control, where p < 0.05. (D). Ingenuity’s pathway analysis of DRAK2 mediated putative
genes, and biological pathways are depicted using a color-coded heatmap. The color intensity of the
squares in the heatmaps reflects the strength of the absolute z-score for predictions (orange = positive,
blue = negative). The size of the squares reflects the z-score values. The top five molecular and cellular
functions deregulated in MEC1 cells upon DRAK2 knockdown are given in the lower panel.
3. Discussion
Recent advances in the understanding of CLL genomics have increased the availability of molecular
markers for prediction of prognosis and guiding of treatment [5,30]. Assessment of the predictive
molecular markers, such as TP53 and IGHV, prior to treatment assignment, is a recommendation
of most current guidelines for CLL management. In addition, several prognostic markers have
been reported in CLL [4,8,31]. Certain consistently validated prognostic factors are now integrated
into prognostic score determination. The discovery of new prognostic biomarkers is improving our
understanding of the underlying biology and natural history of CLL, leading to the development
of new therapeutic strategies [31]. In this study, low expression levels of DRAK2 were significantly
associated with an unfavorable outcome in CLL and specifically within the good risk (low risk) subtype
with 13q14 deletions. DRAK2 expression was found to be a significant, independent marker for OS,
in multivariate analysis, even when established prognostic markers, such as IGHV status and 17p
deletion, were included within the model. These findings highlight DRAK2 as a possible prognostic
marker with potential clinical impact. However, it remains essential to validate the impact of DRAK2
on overall survival in larger cohorts. Deletion of 13q14 is the most frequent genetic lesion in CLL,
occurring in 50–60% of cases. This region contains the micro RNA cluster, including the microRNAs,
miR15A, and miR16A, which inhibits the expression of key regulators of apoptosis and cell cycle
in normal cells [32]. Importantly, the inclusion of a reduced level of DRAK2 as an additional risk
stratification marker will identify patients with more aggressive disease among the good risk (low risk)
subtype with 13q deletions.
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Although this study showed a positive correlation between DRAK2 and DAPK1, DAPK1 expression
was not an indicator of prognosis, nor was it associated with other clinical markers, as reported
previously. In this earlier study, increased DAPK1 promoter methylation was observed within a family
of seven individuals and 62 sporadic CLL samples, implicating that loss or reduced expression of
DAPK1 may be linked to a heritable predisposition to CLL [19]. However, reduced RNA expression
of DAPK1 was reported from a comparison of 50 unselected cells against normal CD19+ B cells,
using semi-quantitative RT-PCR analysis, different from the comparison performed here. Our study
compared total RNA expression from a heterogeneous cohort of 102 samples, including sporadic CLL,
but no familial cases, against normal RNA from PBMC, not CD19+ B cells. While it is possible that the
DAPK1 promoter methylation mark may play a role in hereditary CLL, our study has shown that total
RNA expression of DAPK1 is not a prognostic marker in sporadic, randomly selected CLL. However,
we cannot rule out this study was not adequately powered to detect significant differences to validate
DAPK1 as a prognostic marker. Nonetheless, the positive correlation between DRAK2 and DAPK1
may be indicative of their synergistic roles in apoptosis, with DRAK2 acting as the main inducer of cell
death in sporadic CLL.
In agreement with clinical data, lack of DRAK2 increased cell viability and prolonged cell
proliferation in MEC1 cells, which indicate a possible tumor suppressor role for DRAK2 in CLL.
These observations are similar to previously reported results of the induction of apoptosis through
DRAK2 overexpression in pancreatic beta cells upon free fatty acid stimulation [29]. Moreover, DRAK2
kinase activity-dependent apoptosis-like cell death was observed in adenocarcinoma-derived, ACL-15,
cells upon UV irradiation [27]. Conversely, Drak2−/− T-cells were shown to be more susceptible to
intrinsic apoptosis [33], suggesting that DRAK2 promotes survival of T-cells during clonal expansion
following antigenic stimulation. Thus, the effect of DRAK2 on apoptosis appears to be pro- or
anti-apoptotic, depending on cell type, which in CLL appears to be pro-apoptotic. Downregulation of
DRAK2 in CLL and its association with apoptotic regulators could be events required for the leukemic
cells to escape cell death, as cell viability increases due to DRAK2 downregulation in CLL.
The key apoptotic regulators, such as Bcl-2 family proteins and caspases that mediate the
intrinsic as well as extrinsic apoptotic pathways, showed deregulation upon DRAK2 knockdown
in our transcriptomic data. The differentially expressed genes cluster around NF-κB, ERK, PI3K,
and VEGF signaling nexus (Figure S5). Indeed in CLL signaling/transcriptional pathways, including
MAPK, PI3K/AKT, Wnt/β-catenin, and NF-κB that promote cell survival have been reported to be
deregulated [4,34,35]. In normal B lymphocytes, the stimulation of B-cell receptor signaling triggers
recruitment and activation of Syk kinase, which subsequently activates various downstream effector
enzymes, including protein kinase C (PKC), phosphatidylinositol 3-kinase (PI3K), and phospholipase
Cγ2 [36]. These signaling complexes regulate key downstream pathways, such as AKT, ERK, c-Jun
NH2-terminal kinase, and p38, that determine the B-cell fate [4,5,34]. Several studies have suggested
that AKT activation promotes CLL cell survival following BCR engagement [37]. In the context of T-cells,
TCR activation determines the accumulation of DRAK2 in PKC and MAP kinase-dependent manner.
However, a prominent feature of CLL B-cells is the low level of surface IgM expression and distinct
B-cell receptor (BCR) signaling compared to normal B cells with low-level IgM expression [38]. Further,
dysregulation of the BCR signaling in CLL is characterized by constitutively active phosphorylation
of certain kinases, such as Lyn and Syk that also triggers cell survival pathways. A number of the
above-mentioned pathways could therefore be possibly involved in DRAK2 mediated cell survival
and apoptotic functions that we have observed here. However, systematic validation of the impact of
DRAK2 on the common apoptotic and the survival pathway members and their functional implications
is necessary to fully elucidate the molecular mechanism of DRAK2 in CLL.
Although the role of DRAK2 as a tumor suppressor is evident from the CLL patient cohort and
cell line experiments, the mechanism through which these functions are implemented needs to be
investigated. Further delineation of DRAK2 mediated signaling pathways that regulate cell proliferation
and pro-survival pathways, such as AKT/ERK, Syk/Lyn, and Wnt/β-catenin, in patient-derived CLL
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cells from both treatment naïve and refractory cases will allow us to better understand the role of
DRAK2 in CLL biology and assist in the identification of new drug targets in this disease.
4. Materials and Methods
4.1. Patients and Cell Isolation
Peripheral blood samples (n = 102) from CLL patients were collected in EDTA-coated tubes.
Informed consent was obtained in accordance with the Declaration of Helsinki, and with approval from
the NHS Research Ethics Committee. These samples were processed immediately using Lymphoprep
(Axis Shield, Cambridgeshire, UK). CLL patient sample collection, processing, and storage were carried
out in accordance with the regulations of the Human Tissue Act 2004 (UK). The research was conducted
using samples obtained through the Newcastle Biobank (17/NE/0361).
4.2. Experimental Model and Nucleofection
Human chronic B-cell leukemia MEC-1 cell line (DSMZ no: ACC 497) was purchased from
DSMZ and used as an experimental model. MEC1 is an EBV transformed line and thus proliferates
in culture, making it useful for studies including gene manipulation. Although the MEC-1 line
does not recapitulate all the features of CLL, it was used as a model to examine the function
of DRAK2 in human B cells. The cells were mostly used for experiments between passages
11 and 19 after thawing fresh cells. Cells were grown in IMDM medium supplemented with
10% fetal bovine serum (Gibco) at 37 ◦C in a humidified 5% CO2 atmosphere. Human B cell
Nucleofector Kit™ and Nucleofector™ Platform (Lonza) with Nucleofector Program X-001 was
used in gene manipulation studies. Cells were transiently transfected with 20 nM siRNA (Qiagen,
Hilden, Germany) or 5 µg plasmid DNA (Addgene, Watertown, MA, USA) to obtain DRAK2
knockdown or overexpression, respectively. Please refer to Supplementary Materials Table S2
for antibodies. Cells were transfected for 18 h using sequences specific for DRAK2 gene (mix of
four different siRNA: 5′-TGGTTAGACAATGTATATCAA-3′, 5′-CTGAGATAGCTCTGCAGATAA-3′
5′-CACGAGATTGCTGTGCTTGAA-3′ and 5′-AGCATATATGTTGTTAACTCA-3′; upper strands only)
or negative control siRNA (Qiagen); in overexpression experiments, cells were transfected for 24 h using
control (empty/mock) pEGFP-N1-FLAG vector (Addgene; 60360) or pEGFP-N1-FLAG vector with
DRAK2 corresponded to full-length cDNA sequence (ORF of serine/threonine kinase 17b (STK17B)).
DRAK2 encoding cDNA was cloned into pEGFP-N1-FLAG using BamH1 and Mlul. Transfection
efficiency, in this case, was verified based on the level of EGFP positive cells.
4.3. RNA Extraction and qPCR
Total RNA was extracted from PBMCs using the GeneJet RNA purification kit (Thermo Scientific).
Concentration and purity of the total RNA samples were measured using a NanoDrop ND-1000
Spectrophotometer. cDNA was synthesized with a high-Capacity cDNA synthesis kit (Life Technologies)
following the manufacturer’s protocol. Relative quantification of DAPK1, DRAK2, and TGFBR1 RNA
expression was performed by qPCR based on TaqMan chemistry and carried out in an Applied
Biosystems Viia 7 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). GAPDH was
used as a reference for the normalization of qPCR and a pool of five RNA samples extracted from
peripheral blood of five healthy donors was used as a calibrator. All qPCR reactions were performed
in biological duplicate and technical triplicates to assess data reproducibility.
TaqMan probes used for this study were: Hs02758991_g1 (GAPDH), Hs00892459_m1 (DRAK2),
Hs00234480_m1 (DAPK1), Hs00610320_m1 (TGFBR1) (Supplementary Materials Table S1).
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4.4. Expression and Data Analysis
Calculations for RNA expression were made using the comparative CT (2–∆∆Ct) method.
The potential diagnostic value of DAPK1 and DRAK2 RNA expression was assessed by a ROC
curve to identify optimal cut-off points (Figure S1). DAPK1 and DRAK2 expression was then split at
this diagnostic cut-off, and the resulting dichotomous variable was included in a Kaplan-Meier overall
survival (OS) analysis. Prognostic variables associated with OS were identified through univariate
analysis by Cox regression models. The hazard ratio (HR) and 95% confidence interval (CI) were
calculated using Cox regression models. The independent prognostic variables associated with OS
were confirmed by multivariate analysis using the Cox proportional hazards model. Any differences
between OS curves were evaluated using the log-rank test. In the correlation analysis reported,
all variables were treated as categorical. All statistical calculations were performed using GraphPad
Prism 6, and SPSS Statistics v23 (see Supplementary Materials). Pearson’s test was used to assess the
correlation between categorical variables. Spearman’s test was used to assess the correlation between
continuous variables. The Mann-Whitney U test was used to compare data in subgroups. Differences
were considered statistically significant when p-value was <0.05.
4.5. Cell Viability Assay
Cell viability was determined with the application of the CellTiter-Glo® Luminescent Cell Viability
Assay (Promega), according to the manufacturer’s instructions. Cells with different status of DRAK2
were analyzed at different time points from the beginning of the transfection process; the zero h
time point is regarded to be the optimal time point for incubation of cells with siRNA or plasmid
DNA (equivalent to 18 and 24 h, respectively). Luminescence was calculated using a FLUOstar
Omega microplate reader and MARS Data Analysis Software (BMG Labtech, Ortenberg, Germany).
The relative number of viable cells compared to the control MEC-1 cellular variant was determined.
4.6. EdU Cell Proliferation Assay
Cell proliferation was evaluated by cell counting following EdU (5-ethynyl-2′-deoxiuridine)
incubation with the application of Click-iT® EdU Imaging Kit (C10339, Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Briefly, in order to downregulate or overexpress the
level of DRAK2, MEC1 cells were subjected to siRNA or plasmid DNA transfection (via nucleofection)
protocol and then incubated with 5 uM EdU (soluble in DMSO) conjugated with AlexaFluor®
azide (AlexaFluor®, Thermo Fisher Scientific, Waltham, MA, USA) to determine the number of
proliferating cells. As a negative control, all cellular variants (with different DRAK2 status) were
also treated with a corresponding amount of the solvent (DMSO). After 18 or 24 h (for DRAK2
knock-down or overexpression, respectively) from the transfection start point, cells were fixed in 0.4%
formaldehyde/PBS, permeabilized with 0.3% Triton X100/PBS and smeared onto glass microscopic
slides. Cells were washed twice with 3% BSA/PBS and once with PBS. Slides were mounted with DAPI
containing HardSet medium (Vectashield; DAKO) and analyzed using an epifluorescence microscope
(ZEISS Axio Imager Z1) and 5–6 images (objective 40×) of each experimental variant, corresponding to
at least 100 cells, were taken. Numbers of positively stained (red) and negative (blue) cells/nuclei were
calculated using ImageJ software, and relative proliferation values (percentage of EdU positive cells)
were determined.
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4.7. Trypan Blue Assay
Cell viability and proliferation were also evaluated by cell counting following the trypan blue
(Gibco) exclusion assay. Cells were counted at two time points: (i) after 24 h (zero time point) or
(ii) 48 h (24 h time point) of continuous incubation with siRNA or plasmid DNA. The relative numbers
of viable cells (percentage) compared to the control MEC-1 cellular variant was determined.
4.8. Apoptosis Induction
Apoptosis was assessed using PE Annexin V Apoptosis Detection Kit I (BD Pharmingen, San Diego,
CA, USA) according to the manufacturer’s instruction. All analyses were performed with the
application of viable cells. Assays were conducted 18 h post silencing and 24 h post overexpression.
Cells were stained with viability marker (7-AAD) and Annexin V PE-conjugate. Twenty thousand
events were counted in each sample and the relative percentage of cells in the different fraction was
determined—quadrants representing healthy cells, necrotic cells, and early and late apoptotic cells.
4.9. Gene Expression Level Analyses: Microarrays and qRT-PCR
Total RNA was extracted from 1 × 106 MEC-1 cells using the RNeasy Mini Kit (Qiagen) and
treated in solution with TURBO DNA-free™ Kit (Invitrogen, Renfrew, UK) or on-column with DNase,
using the RNase-Free DNase Set (Qiagen). Quality and quantity of obtained RNA were analyzed by
the Eukaryote Total RNA Nano Assay on an Agilent 2100 Bioanalyzer (RNA integrity numbers >8)
and NanoDrop ND-1000 Spectrophotometer, respectively. Transcriptome profiling was performed
by AROS Applied Biotechnology (Aarhus, Denmark) using GeneChip Human Transcriptome Array
2.0. Array data processing, background correction, normalization, and quality control checks were
performed using the Transcriptome Analysis Console (TAC) Software (Thermo Fisher Scientific, UK).
Differentially expressed genes (in comparison to the control sample) were selected. Genes were
considered as significantly changed when: (i) ANOVA p-value < 0.05 and (ii) fold change (linear) was
<−1.5 or > 1.5. Pathway analysis was performed using Ingenuity Pathway Analysis (IPA) Software
(Qiagen, Manchester, UK). The data discussed in this article will be deposited in NCBI Gene Expression
Omnibus and accessible through GEO Series accession number.
For qRT-PCR analyses, purified RNA was subjected to a two-step RT-PCR reactions.
cDNA synthesis was carried out with the High-Capacity cDNA synthesis kit (Life Technologies);
amounts corresponding to 50 ng of RNA were used as templates. Transcript levels of selected genes
were quantified by qRT-PCR (Applied Biosystems Viia 7 Real-Time PCR System) using SYBR Green dye
or TaqMan probes. All reactions were carried out in triplicate, and expression levels were normalized
according to the GAPDH housekeeping gene. Sequences of primers and TaqMan probes used are
presented in Supplementary Materials Table S1.
5. Conclusions
In summary, we have shown for the first time that DRAK2 expression is linked to Overall Survival
(OS) in CLL patients, potentially through regulation of cell survival and proliferation critical for
leukemic cell fate. The transcriptomic data indicates the possible signaling molecules, including NFkB,
BCL-2, and ERK to participate in DRAK2 mediated functions. It will therefore be informative to further
investigate molecular signaling pathways and mechanistic details of DRAK2 mediated action in CLL
to completely validate as a target for monitoring CLL pathogenesis and progression.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/20/7663/s1,
Figure S1: ROC analysis and impact of DAPK1 on CLL overall survival. Figure S2: DRAK2 and DAPK1 expression
distribution across relevant clinical and molecular CLL subtypes. Figure S3: Characterisation of experimental
model. Figure S4: Coding and uncoding transcripts deregulated upon DRAK2 knockdown in MEC1 cells.
Figure S5: DRAK2 mediated signalling networks implicated in various biological processes and disease conditions.
Table S1: TaqMan probes and primers sequences used in the PCR analyses. Table S2: Antibodies used in Western
blot and immunofluorescence analyses.
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